Stay updated on Cabozantinib Pembrolizumab Combo in Advanced Melanoma Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib Pembrolizumab Combo in Advanced Melanoma Clinical Trial page.

Latest updates to the Cabozantinib Pembrolizumab Combo in Advanced Melanoma Clinical Trial page
- Check7 days agoChange DetectedPage revision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check14 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check36 days agoChange DetectedSite revision updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check51 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check72 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2; no substantive content changes to the study details are visible in the screenshots.SummaryDifference0.1%

- Check80 days agoChange DetectedThis study was terminated early due to changes in melanoma treatment, with termination dated 2026-01-29. The recruitment status 'Active, not recruiting' was removed from the record.SummaryDifference0.5%

- Check87 days agoChange DetectedThe page now shows a glossary, adds a 'Last Update Submitted that Met QC Criteria' field, a 'No FEAR Act Data' indicator, and a 'Revision: v3.4.0' note. The previous 'Last Update Submitted that met QC Criteria' field, FEAR Act wording, and the older 'Revision: v3.3.4' version have been removed.SummaryDifference0.2%

Stay in the know with updates to Cabozantinib Pembrolizumab Combo in Advanced Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib Pembrolizumab Combo in Advanced Melanoma Clinical Trial page.